Avastin Prescribing

HIGHLIGHTS OF PRESCRIBING INFORMATION First-Line Non−squamous non−small cell lung cancer (2.
3)
These highlights do not include all the information needed to use • 15 mg/kg every 3 weeks with carboplatin and paclitaxel
AVASTIN safely and effectively. See full prescribing information for Recurrent glioblastoma (2.4)
AVASTIN. • 10 mg/kg every 2 weeks
Metastatic renal cell cancer (2.5)
AVASTIN (bevacizumab) injection, for intravenous use
®
• 10 mg/kg every 2 weeks with interferon alfa
Persistent, recurrent, or metastatic cervical cancer (2.6)
Initial U.S. Approval: 2004
• 15 mg/kg every 3 weeks with paclitaxel and cisplatin, or paclitaxel and
topotecan
WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary
AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE peritoneal cancer (2.7)
See full prescribing information for complete boxed warning. • 10 mg/kg every 2 weeks with paclitaxel, pegylated liposomal doxorubicin,
• Gastrointestinal Perforations: Discontinue for gastrointestinal or topotecan given every week
perforation. (5.1) • 15 mg/kg every 3 weeks with topotecan given every 3 weeks
• Surgery and Wound Healing Complications: Discontinue in Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary
patients who develop wound healing complications that require peritoneal cancer (2.7)
medical intervention. Withhold for at least 28 days prior to • 15 mg/kg every 3 weeks with carboplatin and paclitaxel for 6-8 cycles,
elective surgery. Do not administer Avastin for at least 28 days followed by 15 mg/kg every 3 weeks as a single agent
after surgery and until the wound is fully healed. (5.2) • 15 mg/kg every 3 weeks with carboplatin and gemcitabine for 6-10 cycles,
• Hemorrhage: Severe or fatal hemorrhages have occurred. Do not followed by 15 mg/kg every 3 weeks as a single agent
administer for recent hemoptysis. Discontinue for Grade 3-4 Administer as an intravenous infusion. (2.8)
hemorrhage (5.3) -----------------------DOSAGE FORMS AND STRENGTHS--------------------
Injection: 100 mg/4 mL or 400 mg/16 mL, single dose vial (3)
-------------------------RECENT MAJOR CHANGES-----------------------------
---------------------------CONTRAINDICATIONS---------------------------------
Indications and Usage, Recurrent Glioblastoma (1.3) 12/2017
Dosage and Administration, Recurrent Glioblastoma (2.4) 12/2017 None (4)
Warnings and Precautions, Congestive Heart Failure (5.12) 12/2017 -----------------------WARNINGS AND PRECAUTIONS------------------------
---------------------------INDICATIONS AND USAGE---------------------------- • Perforation or Fistula: Discontinue for tracheoesophageal fistula, grade 4
Avastin is a vascular endothelial growth factor directed antibody indicated for fistula, or necrotizing fasciitis. (5.1)
the treatment of: • Arterial Thromboembolic Events (ATE): Discontinue for severe ATE.
(5.4)
• Metastatic colorectal cancer, in combination with intravenous • Venous Thromboembolic Events (VTE): Discontinue for Grade 4 VTE.
5-fluorouracil-based chemotherapy for first- or second-line treatment. (1.1) (5.5)
• Metastatic colorectal cancer, in combination with fluoropyrimidine- • Hypertension: Monitor blood pressure and treat hypertension. Withhold if
irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for not medically controlled; resume once controlled. Discontinue for
second-line treatment in patients who have progressed on a first-line hypertensive crisis or hypertensive encephalopathy. (5.6)
Avastin-containing regimen. (1.1) • Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue.
(5.7)
Limitation of Use: Avastin is not indicated for adjuvant treatment of colon • Renal Injury and Proteinuria: Monitor urine protein. Discontinue for
cancer. (1.1) nephrotic syndrome. Withhold until less than 2 grams of protein in urine.
(5.8)
• Unresectable, locally advanced, recurrent or metastatic non-squamous • Infusion Reactions: Decrease rate for infusion reactions. Discontinue for
non-small cell lung cancer, in combination with carboplatin and paclitaxel severe infusion reactions and administer medical therapy. (5.9)
for first-line treatment. (1.2) • Embryo-fetal Toxicity: Advise females of potential risk to fetus and need
• Recurrent glioblastoma in adults. (1.3) for use of effective contraception. (5.10, 8.1, 8.3)
• Metastatic renal cell carcinoma in combination with interferon alfa. (1.4) • Ovarian Failure: Advise females of the potential risk. (5.11, 8.3)
• Persistent, recurrent, or metastatic cervical cancer, in combination with • Congestive Heart Failure (CHF): Discontinue if CHF (5.12).
paclitaxel and cisplatin, or paclitaxel and topotecan. (1.5)
• Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer ------------------------------ADVERSE REACTIONS------------------------------
that is:
o platinum-resistant in combination with paclitaxel, pegylated Most common adverse reactions incidence (incidence > 10%) are epistaxis,
liposomal doxorubicin, or topotecan headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal
o platinum-sensitive in combination with carboplatin and paclitaxel or hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis. (6.1)
carboplatin and gemcitabine followed by Avastin as a single agent
(1.6) To report SUSPECTED ADVERSE REACTIONS, contact Genentech,
Inc. at 1-888-835-2555 or FDA at 1-800-FDA-1088 or
------------------------DOSAGE AND ADMINISTRATION--------------------- www.fda.gov/medwatch.
Do not administer Avastin for 28 days following major surgery and until -----------------------------USE IN SPECIFIC POPULATIONS------------------
surgical wound is fully healed. (2.1)
Metastatic colorectal cancer (2.2) • Lactation: Advise not to breast feed. (8.2)
• 5 mg/kg every 2 weeks with bolus-IFL
• 10 mg/kg every 2 weeks with FOLFOX4 See 17 for PATIENT COUNSELING INFORMATION.
• 5 mg/ kg every 2 weeks or 7.5 mg/kg every 3 weeks with Revised: 12/2017
fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based
chemotherapy after progression on a first-line Avastin containing regimen
FULL PRESCRIBING INFORMATION: CONTENTS* 5.11 Ovarian Failure
5.12 Congestive Heart Failure
WARNING: GASTROINTESTINAL PERFORATIONS, 6 ADVERSE REACTIONS
SURGERY AND WOUND HEALING COMPLICATIONS, and 6.1 Clinical Trial Experience
HEMORRHAGE 6.2 Immunogenicity
1 INDICATIONS AND USAGE 6.3 Postmarketing Experience
1.1 Metastatic Colorectal Cancer (mCRC) 7 DRUG INTERACTIONS
1.2 First-line Non-Squamous Non−Small Cell Lung Cancer 8 USE IN SPECIFIC POPULATIONS
(NSCLC) 8.1 Pregnancy
1.3 Recurrent Glioblastoma (GBM) 8.2 Lactation
1.4 Metastatic Renal Cell Carcinoma (mRCC) 8.3 Females and Males of Reproductive Potential
1.5 Persistent, Recurrent, or Metastatic Cervical Cancer 8.4 Pediatric Use
1.6 Recurrent Epithelial Ovarian, Fallopian Tube, or Primary 8.5 Geriatric Use
Peritoneal Cancer 10 OVERDOSAGE
2 DOSAGE AND ADMINISTRATION 11 DESCRIPTION
2.1 Important Administration Information 12 CLINICAL PHARMACOLOGY
2.2 Metastatic Colorectal Cancer (mCRC) 12.1 Mechanism of Action
2.3 First-Line Non-Squamous Non-Small Cell Lung Cancer 12.3 Pharmacokinetics
(NSCLC) 13 NONCLINICAL TOXICOLOGY
2.4 Recurrent Glioblastoma (GBM) 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
2.5 Metastatic Renal Cell Carcinoma (mRCC) 13.2 Animal Toxicology and/or Pharmacology
2.6 Persistent, Recurrent, or Metastatic Cervical Cancer 14 CLINICAL STUDIES
2.7 Recurrent Epithelial Ovarian, Fallopian Tube or Primary 14.1 Metastatic Colorectal Cancer (mCRC)
Peritoneal Cancer 14.2 Lack of Efficacy in Adjuvant Treatment of Colon Cancer
2.8 Dose Modifications for Adverse Reactions 14.3 First-Line Non-Squamous Non-Small Cell Lung Cancer
2.9 Preparation and Administration (NSCLC)
3 DOSAGE FORMS AND STRENGTHS 14.4 Recurrent Glioblastoma (GBM)
4 CONTRAINDICATIONS 14.5 Metastatic Renal Cell Carcinoma (mRCC)
5 WARNINGS AND PRECAUTIONS 14.6 Persistent, Recurrent, or Metastatic Cervical Cancer
5.1 Gastrointestinal Perforations and Fistulae 14.7 Platinum-Resistant Recurrent Epithelial Ovarian,
5.2 Surgery and Wound Healing Complications Fallopian Tube, or Primary Peritoneal Cancer
5.3 Hemorrhage 14.8 Platinum-Sensitive Recurrent Epithelial Ovarian,
5.4 Arterial Thromboembolic Events Fallopian Tube, or Primary Peritoneal Cancer
5.5 Venous Thromboembolic Events 16 HOW SUPPLIED/STORAGE AND HANDLING
5.6 Hypertension 17 PATIENT COUNSELING INFORMATION
5.7 Posterior Reversible Encephalopathy Syndrome (PRES)
5.8 Renal Injury and Proteinuria * Sections or subsections omitted from the Full Prescribing Information are
5.9 Infusion Reactions not listed.
5.10 Embryo-Fetal Toxicity
FULL PRESCRIBING INFORMATION
WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND

HEALING COMPLICATIONS, and HEMORRHAGE
Gastrointestinal Perforations: The incidence of gastrointestinal perforation, some fatal, in
patients receiving Avastin ranges from 0.3% to 3%. Discontinue Avastin in patients who
develop gastrointestinal perforation [see Warnings and Precautions (5.1)].
Surgery and Wound Healing Complications: The incidence of wound healing and surgical
complications, including serious and fatal complications, is increased in patients receiving
Avastin. Discontinue Avastin in patients who develop wound healing complications that
require medical intervention. Withhold Avastin at least 28 days prior to elective surgery. Do
not administer Avastin for at least 28 days after surgery, and until the wound is fully healed
[see Warnings and Precautions (5.2)].
Hemorrhages: Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding,

hematemesis, CNS hemorrhage, epistaxis, and vaginal bleeding occur up to 5-fold more
frequently in patients receiving Avastin. Do not administer Avastin to patients with a recent
history of hemoptysis. Discontinue in patients who develop Grade 3-4 hemorrhage [see
Warnings and Precautions (5.3)].
1 INDICATIONS AND USAGE

1.1 Metastatic Colorectal Cancer (mCRC)
Avastin, in combination with intravenous 5-fluorouracil-based chemotherapy, is indicated for the
first- or second-line treatment of patients with metastatic colorectal cancer.
Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based

chemotherapy, is indicated for the second-line treatment of patients with metastatic colorectal cancer
who have progressed on a first-line Avastin-containing regimen.
Limitation of Use: Avastin is not indicated for adjuvant treatment of colon cancer [see Clinical
Studies (14.2)].
1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer (NSCLC)

Avastin, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of
patients with unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell
lung cancer.
1.3 Recurrent Glioblastoma (GBM)

Avastin is indicated for the treatment of recurrent glioblastoma in adults.
1.4 Metastatic Renal Cell Carcinoma (mRCC)

Avastin, in combination with interferon alfa, is indicated for the treatment of metastatic renal cell
carcinoma.
1.5 Persistent, Recurrent, or Metastatic Cervical Cancer

Avastin, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the
treatment of patients with persistent, recurrent, or metastatic cervical cancer.
1.6 Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated
for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or
primary peritoneal cancer who received no more than 2 prior chemotherapy regimens.
Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine,
followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-
sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
2 DOSAGE AND ADMINISTRATION

2.1 Important Administration Information
Do not administer Avastin until at least 28 days following surgery and the wound is fully healed.

The recommended dose when Avastin is administered in combination with intravenous
5-fluorouracil-based chemotherapy is:
• 5 mg/kg every 2 weeks intravenously in combination with bolus-IFL.
• 10 mg/kg every 2 weeks intravenously in combination with FOLFOX4.
• 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks in combination
with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in
patients who have progressed on a first-line Avastin-containing regimen.
2.3 First-Line Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

The recommended dose is 15 mg/kg intravenously every 3 weeks in combination with carboplatin
and paclitaxel.

The recommended dose is 10 mg/kg intravenously every 2 weeks.

The recommended dose is 10 mg/kg intravenously every 2 weeks in combination with interferon
alfa.

The recommended dose of Avastin is 15 mg/kg intravenously every 3 weeks in combination with
paclitaxel and cisplatin or in combination with paclitaxel and topotecan.
2.7 Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Platinum Resistant
The recommended dose is 10 mg/kg intravenously every 2 weeks in combination with paclitaxel,
pegylated liposomal doxorubicin, or topotecan (every week).
The recommended dose is 15 mg/kg intravenously every 3 weeks in combination with topotecan
(every 3 weeks).
Platinum Sensitive
The recommended dose is 15 mg/kg intravenously every 3 weeks, in combination with carboplatin
and paclitaxel for 6 to 8 cycles, followed by Avastin 15 mg/kg every 3 weeks as a single agent until
disease progression.
The recommended dose is 15 mg/kg intravenously every 3 weeks, in combination with carboplatin
and gemcitabine for 6 to 10 cycles, followed by Avastin 15 mg/kg every 3 weeks as a single agent
until disease progression.
2.8 Dose Modifications for Adverse Reactions

Table 1 describes dose modifications for specific adverse reactions [see Warnings and Precautions
(5)]. No dose reductions for Avastin are recommended.
Table 1: Dose Modifications for Adverse Reactions
Adverse Reaction Severity Dose Modification

Gastrointestinal Perforation • Gastrointestinal perforation, any grade Discontinue Avastin
and fistulae [see Warnings • Tracheoesophageal fistula, any grade
and Precautions (5.1)]. • Fistula, Grade 4
• Fistula formation involving any internal
organ
Wound Healing • Wound healing complications requiring Discontinue Avastin
Complications [see medical intervention
Warnings and Precautions • Necrotizing fasciitis
(5.2)].
Hemorrhage [see Warnings • Grade 3 or 4 Discontinue Avastin
and Precautions (5.3)]. • Recent history of hemoptysis of 1/2 Withhold Avastin
teaspoon (2.5 mL) or more
Thromboembolic Events [see • Arterial thromboembolism, severe Discontinue Avastin
Warnings and Precautions • Venous thromboembolism, Grade 4 Discontinue Avastin
(5.4, 5.5)].
Hypertension [see Warnings • Hypertensive crisis Discontinue Avastin

and Precautions (5.6)]. • Hypertensive encephalopathy
• Hypertension, severe Withhold Avastin if not
controlled with medical
management; resume once
controlled
Posterior Reversible • Any Discontinue Avastin
Encephalopathy Syndrome
(PRES) [see Warnings and
Precautions (5.7)].
Renal Toxicity and • Nephrotic syndrome Discontinue Avastin
Proteinuria [see Warnings • Proteinuria greater than or equal to Withhold Avastin until
and Precautions (5.8)]. 2 grams per 24 hours in absence of proteinuria less than 2 grams
nephrotic syndrome per 24 hours
Adverse Reaction Severity Dose Modification
Infusion Reaction [see • Severe infusion reaction Discontinue Avastin
Warnings and Precautions • Clinically significant Interrupt infusion; resume at a
(5.10)]. decreased rate of infusion after
symptoms resolve
• Mild, clinically insignificant Decrease infusion rate

Congestive Heart Failure [see Any Discontinue Avastin
Warnings and Precautions
(5.12)].
2.9 Preparation and Administration

Administration
• Administer as an intravenous infusion.
• First infusion: Administer infusion over 90 minutes.
• Subsequent infusions: Administer second infusion over 60 minutes if first infusion is tolerated.
Administer all subsequent infusions over 30 minutes if second infusion over 60 minutes is
tolerated.
Preparation
• Use appropriate aseptic technique.
• Parenteral drug products should be inspected visually for particulate matter and discoloration
prior to administration.
• Withdraw necessary amount of Avastin and dilute in a total volume of 100 mL of 0.9% Sodium
Chloride Injection, USP. DO NOT ADMINISTER OR MIX WITH DEXTROSE SOLUTION.
• Discard any unused portion left in a vial, as the product contains no preservatives.
• Store diluted Avastin solution at 2−8°C (36−46°F) for up to 8 hours.
• No incompatibilities between Avastin and polyvinylchloride or polyolefin bags have been
observed.
3 DOSAGE FORMS AND STRENGTHS

Injection: 100 mg/4 mL (25 mg/mL) or 400 mg/16 mL (25 mg/mL) as a clear to slightly opalescent,
colorless to pale brown solution in single-dose vial
4 CONTRAINDICATIONS
None.
5 WARNINGS AND PRECAUTIONS

5.1 Gastrointestinal Perforations and Fistulae
Serious and sometimes fatal gastrointestinal perforation occur at a higher incidence in patients
receiving Avastin compared to patients receiving chemotherapy. The incidence ranged from 0.3% to
3% across clinical studies, with the highest incidence in patients with a history of prior pelvic
radiation. Perforation can be complicated by intra-abdominal abscess, fistula formation, and the need
for diverting ostomies. The majority of perforations occurred within 50 days of the first dose.
Serious fistulae (including, tracheoesophageal, bronchopleural, biliary, vaginal, renal and bladder
sites) occur at a higher incidence in patients receiving Avastin compared to patients receiving
chemotherapy. The incidence ranged from < 1% to 1.8% across clinical studies, with the highest
incidence in patients with cervical cancer. The majority of fistulae occurred within 6 months of the
first dose. Patients who develop a gastrointestinal vaginal fistula may also have a bowel obstruction
and require surgical intervention, as well as a diverting ostomy.
Avoid Avastin in patients with ovarian cancer who have evidence of recto-sigmoid involvement by
pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction.
Discontinue in patients who develop gastrointestinal perforation, tracheoesophageal fistula or any
Grade 4 fistula. Discontinue in patients with fistula formation involving any internal organ [see
Adverse Reactions (6.1)].
5.2 Surgery and Wound Healing Complications

In a controlled clinical study in which Avastin was not administered within 28 days of major surgical
procedures, the incidence of wound healing complications, including serious and fatal complications,
was 15% in patients with mCRC who underwent surgery while receiving Avastin and 4% in patients
who did not receive Avastin. In a controlled clinical study in patients with relapsed or recurrent
GBM, the incidence of wound healing events was 5% in patients who received Avastin and 0.7% in
patients who did not receive Avastin [see Adverse Reactions (6.1)].
Discontinue Avastin in patients with wound healing complications requiring medical intervention.
Withhold for at least 28 days prior to elective surgery. Do not administer for at least 28 days
following surgery and until the wound is fully healed.
Necrotizing fasciitis including fatal cases, has been reported in patients receiving Avastin, usually
secondary to wound healing complications, gastrointestinal perforation or fistula formation.
Discontinue in patients who develop necrotizing fasciitis [see Adverse Reactions (6.3)].
5.3 Hemorrhage
Avastin can result in two distinct patterns of bleeding: minor hemorrhage, most commonly Grade 1
epistaxis; and serious, and in some cases fatal, hemorrhage. Severe or fatal hemorrhage, including
hemoptysis, gastrointestinal bleeding, hematemesis, CNS hemorrhage, epistaxis, and vaginal
bleeding, occurred up to 5-fold more frequently in patients receiving Avastin compared to patients
receiving chemotherapy alone. Across clinical studies, the incidence of Grades 3-5 hemorrhagic
events ranged from 0.4% to 7% in patients receiving Avastin [see Adverse Reactions (6.1)].
Serious or fatal pulmonary hemorrhage occurred in 31% of patients with squamous NSCLC and 4%
of patients with non-squamous NSCLC receiving Avastin with chemotherapy compared to none of
the patients receiving chemotherapy alone.
Do not administer Avastin to patients with recent history of hemoptysis of 1/2 teaspoon or more of
red blood. Discontinue in patients who develop a Grade 3-4 hemorrhage.
5.4 Arterial Thromboembolic Events

Serious, sometimes fatal, arterial thromboembolic events (ATE) including cerebral infarction,
transient ischemic attacks, myocardial infarction, and angina, occurred at a higher incidence in
patients receiving Avastin compared to patients receiving chemotherapy. Across clinical studies, the
incidence of Grades 3-5 ATE was 5% in patients receiving Avastin with chemotherapy compared to
≤ 2% in patients receiving chemotherapy alone; the highest incidence occurred in patients with
GBM. The risk of developing ATE was increased in patients with a history of arterial
thromboembolism, diabetes, or greater than 65 years old [see Use in Specific Populations (8.5)].
Discontinue in patients who develop a severe ATE. The safety of reinitiating Avastin after an ATE is
resolved is not known.
5.5 Venous Thromboembolic Events

An increased risk of venous thromboembolic events (VTE) was observed across clinical studies. In
Study GOG-0240, Grade 3-4 VTE was reported in 11% of patients receiving Avastin with
chemotherapy compared with 5% of patients receiving chemotherapy alone. In EORTC 26101, the
incidence of Grade 3-4 VTE was 5% in patients receiving Avastin with chemotherapy compared to
2% in patients receiving chemotherapy alone.
Discontinue Avastin in patients with a Grade 4 VTE, including pulmonary embolism [see Adverse
Reactions (6.1)].
5.6 Hypertension
The incidence of severe hypertension is increased in patients receiving Avastin as compared to
patients receiving chemotherapy alone. Across clinical studies, the incidence of Grade 3-4
hypertension ranged from 5% to 18%.
Monitor blood pressure every two to three weeks during treatment with Avastin. Treat with
appropriate anti-hypertensive therapy and monitor blood pressure regularly. Continue to monitor
blood pressure at regular intervals in patients with Avastin-induced or -exacerbated hypertension
after discontinuing Avastin. Withhold Avastin in patients with severe hypertension that is not
controlled with medical management; resume once controlled with medical management.
Discontinue in patients who develop hypertensive crisis or hypertensive encephalopathy.
5.7 Posterior Reversible Encephalopathy Syndrome (PRES)

PRES was reported in < 0.5% of patients across clinical studies. The onset of symptoms occurred
from 16 hours to 1 year after the first dose. PRES is a neurological disorder which can present with
headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances. Mild
to severe hypertension may be present. Magnetic resonance imaging is necessary to confirm the
diagnosis of PRES.
Discontinue Avastin in patients who develop PRES. Symptoms usually resolve or improve within
days after discontinuing Avastin, although some patients have experienced ongoing neurologic
sequelae. The safety of reinitiating Avastin in patients who developed PRES is not known.
5.8 Renal Injury and Proteinuria

The incidence and severity of proteinuria is higher in patients receiving Avastin as compared to
patients receiving chemotherapy. Grade 3 (defined as urine dipstick 4+ or > 3.5 grams of protein per
24 hours) to Grade 4 (defined as nephrotic syndrome) ranged from 0.7% to 7% in clinical studies.
The overall incidence of proteinuria (all grades) was only adequately assessed in Study BO17705, in
which the incidence was 20%. Median onset of proteinuria was 5.6 months (15 days to 37 months)
after initiating Avastin. Median time to resolution was 6.1 months (95% CI: 2.8, 11.3). Proteinuria
did not resolve in 40% of patients after median follow-up of 11.2 months and required
discontinuation of Avastin in 30% of the patients who developed proteinuria.
In an exploratory, pooled analysis of patients from seven randomized clinical studies, 5% of patients
receiving Avastin with chemotherapy experienced Grades 2-4 (defined as urine dipstick 2+ or
greater or > 1 gram of protein per 24 hours or nephrotic syndrome) proteinuria. Grades 2-4
proteinuria resolved in 74% of patients. Avastin was reinitiated in 42% of patients. Of the 113
patients who reinitiated Avastin, 48% experienced a second episode of Grade 2-4 proteinuria.
Nephrotic syndrome occurred in < 1% of patients receiving Avastin across clinical studies, in some
instances with fatal outcome. In a published case series, kidney biopsy of 6 patients with proteinuria
showed findings consistent with thrombotic microangiopathy. Results of a retrospective analysis of
5805 patients who received Avastin with chemotherapy and 3713 patients who received
chemotherapy alone, showed higher rates of elevated serum creatinine levels (between 1.5 to 1.9
times baseline levels) in patients who received Avastin. Serum creatinine levels did not return to
baseline in approximately one-third of patients who received Avastin.
Monitor proteinuria by dipstick urine analysis for the development or worsening of proteinuria with
serial urinalyses during Avastin therapy. Patients with a 2+ or greater urine dipstick reading should
undergo further assessment with a 24-hour urine collection. Withhold for proteinuria greater than or
equal to 2 grams per 24 hours and resume when less than 2 grams per 24 hours. Discontinue in
patients who develop nephrotic syndrome.
Data from a postmarketing safety study showed poor correlation between UPCR (Urine
Protein/Creatinine Ratio) and 24-hour urine protein [Pearson Correlation 0.39 (95% CI: 0.17, 0.57)].
5.9 Infusion Reactions

Infusion reactions reported across clinical studies and post-marketing experience include
hypertension, hypertensive crises associated with neurologic signs and symptoms, wheezing, oxygen
desaturation, Grade 3 hypersensitivity, chest pain, headaches, rigors, and diaphoresis. In clinical
studies, infusion reactions with the first dose occurred in < 3% of patients and severe reactions
occurred in 0.2% of patients.
Decrease the rate of infusion for mild, clinically insignificant infusion reactions. Interrupt the
infusion in patients with clinically significant infusion reactions and consider resuming at a slower
rate following resolution. Discontinue in patients who develop a severe infusion reaction and
administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous
antihistamines, bronchodilators and/or oxygen).
5.10 Embryo-Fetal Toxicity

Avastin may cause fetal harm based on its mechanism of action and findings from animal studies.
Congenital malformations were observed with the administration of bevacizumab to pregnant rabbits
during organogenesis every 3 days at a dose as low as a clinical dose of 10 mg/kg. Furthermore,
animal models link angiogenesis and VEGF and VEGFR 2 to critical aspects of female reproduction,
embryo-fetal development, and postnatal development. Advise pregnant women of the potential risk
to a fetus. Advise females of reproductive potential to use effective contraception during treatment
with and for 6 months after the last dose of Avastin [see Use in Specific Populations (8.1, 8.3),
Clinical Pharmacology (12.1)].
5.11 Ovarian Failure

The incidence of ovarian failure was 34% vs. 2% in premenopausal women receiving Avastin with
chemotherapy as compared to those receiving chemotherapy alone for adjuvant treatment of a solid
tumor. After discontinuing Avastin, recovery of ovarian function at all time points during the
post-treatment period was demonstrated in 22% of women receiving Avastin. Recovery of ovarian
function is defined as resumption of menses, a positive serum β-HCG pregnancy test, or a FSH level
< 30 mIU/mL during the post-treatment period. Long-term effects of Avastin on fertility are
unknown. Inform females of reproductive potential of the risk of ovarian failure prior to initiating
Avastin [see Adverse Reactions (6.1), Use in Specific Populations (8.3)].
5.12 Congestive Heart Failure (CHF)

Avastin is not indicated for use with anthracycline-based chemotherapy. The incidence of Grade > 3
left ventricular dysfunction was 1% in patients receiving Avastin compared to 0.6% of patients
receiving chemotherapy alone. Among patients who received prior anthracycline treatment, the rate
of CHF was 4% for patients receiving Avastin with chemotherapy as compared to 0.6% for patients
receiving chemotherapy alone.
In previously untreated patients with a hematological malignancy, the incidence of CHF and decline
in left ventricular ejection fraction (LVEF) were increased in patients receiving Avastin with
anthracycline-based chemotherapy compared to patients receiving placebo with the same
chemotherapy regimen. The proportion of patients with a decline in LVEF from baseline of ≥ 20%
or a decline from baseline of 10% to < 50%, was 10% in patients receiving Avastin with
chemotherapy compared to 5% in patients receiving chemotherapy alone. Time to onset of left-
ventricular dysfunction or CHF was 1 to 6 months after the first dose in at least 85% of the patients
and was resolved in 62% of the patients who developed CHF in the Avastin arm compared to 82% in
the placebo arm. Discontinue Avastin in patients who develop CHF.
6 ADVERSE REACTIONS
The following serious adverse reactions are discussed in greater detail in other sections of the
labeling:
• Gastrointestinal Perforations and Fistulae [see Warnings and Precautions (5.1)].
• Surgery and Wound Healing Complications [see Warnings and Precautions (5.2)]
• Hemorrhage [see Warnings and Precautions (5.3)].
• Arterial Thromboembolic Events [see Warnings and Precautions (5.4)].
• Venous Thromboembolic Events [see Warnings and Precautions (5.5)].
• Hypertension [see Warnings and Precautions (5.6)].
• Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.7)].
• Renal Injury and Proteinuria [see Warnings and Precautions (5.8)].
• Infusion Reactions [see Warnings and Precautions (5.9)].
• Ovarian Failure [see Warnings and Precautions (5.11)].
• Congestive Heart Failure [see Warnings and Precautions (5.12).].
6.1 Clinical Trial Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates
observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies
of another drug and may not reflect the rates observed in practice.
The most common adverse reactions observed in patients receiving Avastin as a single agent or in
combination with chemotherapy at a rate > 10%, are epistaxis, headache, hypertension, rhinitis,
proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain and
exfoliative dermatitis.
The safety data below reflect exposure to Avastin in 2919 patients with mCRC, non-squamous
NSCLC, glioblastoma, mRCC, cervical cancer, platinum-resistant or platinum-sensitive recurrent
epithelial ovarian, fallopian tube, or primary peritoneal cancer, including controlled studies
(AVF2107g, E3200, E4599, EORTC 26101, BO17705, GOG-0240, MO22224, AVF4095, GOG-
0213) at the recommended dose and schedule for a median of 6 to 23 doses.
Across clinical studies, Avastin was discontinued in 8% to 22% of patients because of adverse
reactions [see Clinical Studies (14)].
Platinum-Resistant Recurrent Epithelia Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The safety of Avastin was evaluated in 179 patients who received at least one dose of Avastin in a
multicenter, open-label study (MO22224) in which patients were randomized (1:1) to Avastin with
chemotherapy or chemotherapy alone in patients with platinum resistant, recurrent epithelial ovarian,
fallopian tube, or primary peritoneal cancer that recurred within < 6 months from the most recent
platinum based therapy. Patients were randomized to receive Avastin (10 mg/kg every 2 weeks or 15
mg/kg every 3 weeks). Patients had received no more than 2 prior chemotherapy regimens. The trial
excluded patients with evidence of recto-sigmoid involvement by pelvic examination or bowel
involvement on CT scan or clinical symptoms of bowel obstruction. Patients were treated until
disease progression or unacceptable toxicity. Forty percent of patients on the chemotherapy alone
arm received Avastin alone upon progression. The demographics of the safety population were
similar to the demographics of the efficacy population. Adverse reactions are presented in Table 2.
Table 2: Grade 2−4 Adverse Reactions Occurring at Higher Incidence ( ≥ 5%) in Patients
Receiving Avastin with Chemotherapy vs. Chemotherapy Alone in Study MO22224
Avastin with Chemotherapy Chemotherapy

Adverse Reactiona
(N=179) (N=181)
Blood and lymphatic system disorders
Neutropenia 31% 25%
General disorders
Mucosal inflammation 13% 6%
Infections
Infection 11% 4%
Nervous system disorders
Peripheral sensory 18% 7%
neuropathy
Renal and urinary disorders
Proteinuria 12% 0.6%
Respiratory, thoracic and mediastinal disorders
Epistaxis 5% 0%
Skin and subcutaneous tissue disorders
Palmar-plantar 11% 5%
erythrodysaesthesia
Vascular disorders
Hypertension 19% 6%
a NCI-CTC version 3
Grade 3-4 adverse reactions occurring at a higher incidence ( ≥ 2%) in 179 patients receiving
Avastin with chemotherapy compared to 181 patients receiving chemotherapy alone were
hypertension (6.7% vs. 1.1%) and palmar-plantar erythrodysaesthesia syndrome (4.5% vs. 1.7%).
Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
double-blind study (AVF4095g) in patients with platinum sensitive recurrent epithelial ovarian,
fallopian tube or primary peritoneal cancer. Patients were randomized (1:1) to receive Avastin (15
mg/kg) or placebo every 3 weeks with carboplatin and gemcitabine for 6 to 10 cycles followed by
Avastin or placebo alone until disease progression or unacceptable toxicity. The demographics of the
safety population were similar to the demographics of the efficacy population. Adverse reactions are
presented in Table 3.
Table 3: Grade 1−5 Adverse Reactions Occurring at a Higher Incidence (≥ 5%) in Patients
Receiving Avastin with Chemotherapy vs. Placebo with Chemotherapy in Study AVF4095g
Avastin with Carboplatin and Placebo with Carboplatin and

Adverse Reactiona Gemcitabine Gemcitabine
(N=247) (N=233)
Thrombocytopenia 58% 51%
Gastrointestinal disorders
Nausea 72% 66%
Diarrhea 38% 29%
Stomatitis 15% 7%
Hemorrhoids 8% 3%
Gingival bleeding 7% 0%
General disorders
Fatigue 82% 75%
Mucosal inflammation 15% 10%
Infections
Sinusitis 15% 9%
Injury and procedural complications
Contusion 17% 9%
Musculoskeletal and connective tissue disorders
Arthralgia 28% 19%
Back pain 21% 13%
Headache 49% 30%
Dizziness 23% 17%
Psychiatric disorders
Insomnia 21% 15%
Proteinuria 20% 3%
Epistaxis 55% 14%
Dyspnea 30% 24%
Cough 26% 18%
Oropharyngeal pain 16% 10%
Dysphonia 13% 3%
Rhinorrhea 10% 4%
Sinus congestion 8% 2%
Vascular disorders
Hypertension 42% 9%
a NCI-CTC version 3
Grade 3−4 adverse reactions occurring at a higher incidence (≥ 2%) in patients receiving Avastin
with chemotherapy compared to placebo with chemotherapy were: thrombocytopenia (40% vs.
34%), nausea (4% vs. 1.3%), fatigue (6% vs. 4%), headache (4% vs. 0.9%), proteinuria (10% vs.
0.4%), dyspnea (4% vs. 1.7%), epistaxis (5% vs. 0.4%), and hypertension (17% vs. 0.9%).
The safety of Avastin was evaluated in an open-label, controlled study, GOG-0213, in 325 patients
with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer,
who have not received more than one previous regimen of chemotherapy. Patients were randomized
(1:1) to receive carboplatin and paclitaxel for 6 to 8 cycles or Avastin (15 mg/kg every 3 weeks)
with carboplatin and paclitaxel for 6 to 8 cycles followed by Avastin as a single agent until disease
progression or unacceptable toxicity. The demographics of the safety population were similar to the
demographics of the efficacy population. Adverse reactions are presented in Table 4.
Table 4: Grade 1−5 Adverse Reactions Occurring at Higher Incidence (≥ 5%) in Patients
Receiving Avastin with Chemotherapy vs. Chemotherapy Alone in Study GOG-0213
Avastin with
Adverse Reactiona Carboplatin and Paclitaxel Carboplatin and Paclitaxel
(N=325) (N=332)
Diarrhea 39% 32%
Abdominal pain 33% 28%
Vomiting 33% 25%
Stomatitis 33% 16%
Metabolism and nutrition disorders
Decreased appetite 35% 25%
Hyperglycemia 31% 24%
Hypomagnesemia 27% 17%
Hyponatremia 17% 6%
Weight decreased 15% 4%
Hypocalcemia 12% 5%
Hypoalbuminemia 11% 6%
Hyperkalemia 9% 3%
Arthralgia 45% 30%
Myalgia 29% 18%
Pain in extremity 25% 14%
Back pain 17% 10%
Muscular weakness 13% 8%
Neck pain 9% 0%
Epistaxis 33% 2%
Dyspnea 30% 25%
Cough 30% 17%
Rhinitis allergic 17% 4%
Nasal mucosal disorder 14% 3%
Avastin with
a
Adverse Reaction Carboplatin and Paclitaxel Carboplatin and Paclitaxel
(N=325) (N=332)
Headache 38% 20%
Dysarthria 14% 2%
Dizziness 13% 8%
Hepatic Disorders
Aspartate aminotransferase 15% 9%
increased
Skin and subcutaneous tissue disorders
Exfoliative rash 23% 16%
Nail disorder 10% 2%
Dry skin 7% 2%
Vascular disorders
Hypertension 42% 3%
Proteinuria 17% 1%
Blood creatinine increased 13% 5%
General disorders
Chest pain 8% 2%
Infections
Sinusitis 7% 2%
a NCI-CTC version 3
Grade 3−4 adverse reactions occurring at a higher incidence (≥ 2%) in patients receiving Avastin
with chemotherapy compared to chemotherapy alone were: hypertension (11% vs. 0.6%), fatigue
(8% vs. 3%), febrile neutropenia (6% vs. 3%), proteinuria (8% vs. 0%), abdominal pain (6% vs.
0.9%), hyponatremia (4% vs. 0.9%), headache (3% vs. 0.9%), and pain in extremity (3% vs. 0%).
Metastatic Renal Cell Carcinoma (mRCC)

multicenter, double-blind study (BO17705) in patients with metastatic renal cell carcinoma. Patients
who had undergone a nephrectomy were randomized (1:1) to receive either Avastin (10 mg/kg every
2 weeks) or placebo with interferon alfa. Patients were treated until disease progression or
unacceptable toxicity. The demographics of the safety population were similar to the demographics
of the efficacy population.
Grade 3-5 adverse reactions occurring at a higher incidence ( >2%) were fatigue (13% vs. 8%),
asthenia (10% vs. 7%), proteinuria (7% vs. 0%), hypertension (6% vs. 1%; including hypertension
and hypertensive crisis), and hemorrhage (3% vs. 0.3%; including epistaxis, small intestinal
hemorrhage, aneurysm ruptured, gastric ulcer hemorrhage, gingival bleeding, hemoptysis,
hemorrhage intracranial, large intestinal hemorrhage, respiratory tract hemorrhage, and traumatic
hematoma). Adverse reactions are presented in Table 5.
Table 5: Grades 1-5 Adverse Reactions Occurring at Higher Incidence (≥ 5%) of Patients
Receiving Avastin vs. Placebo with Interferon Alfa in Study BO17705
Avastin with Interferon Placebo with Interferon

Adverse Reactiona Alfa Alfa
(N=337) (N=304)
Diarrhea 21% 16%
General disorders and administration site conditions
Fatigue 33% 27%
Weight decreased 20% 15%
Myalgia 19% 14%
Back pain 12% 6%
Headache 24% 16%
Proteinuria 20% 3%
Epistaxis 27% 4%
Dysphonia 5% 0%
Vascular disorders
Hypertension 28% 9%
a NCI-CTC version 3
The following adverse reactions were reported at a 5-fold greater incidence in patients receiving
Avastin with interferon-alfa compared to patients receiving placebo with interferon-alfa and not
represented in Table 3: gingival bleeding (13 patients vs. 1 patient); rhinitis (9 vs. 0); blurred vision
(8 vs. 0); gingivitis (8 vs. 1); gastroesophageal reflux disease (8 vs. 1); tinnitus (7 vs. 1); tooth
abscess (7 vs. 0); mouth ulceration (6 vs. 0); acne (5 vs. 0); deafness (5 vs. 0); gastritis (5 vs. 0);
gingival pain (5 vs. 0) and pulmonary embolism (5 vs. 1).
Persistent, Recurrent, or Metastatic Cervical Cancer

multicenter study (GOG-0240) in patients with persistent, recurrent, or metastatic cervical cancer.
Patients were randomized (1:1:1:1) to receive paclitaxel and cisplatin with or without Avastin (15
mg/kg every 3 weeks), or paclitaxel and topotecan with or without Avastin (15 mg/kg every 3
weeks). The demographics of the safety population were similar to the demographics of the efficacy
population. Adverse reactions are presented in Table 6.
Table 6: Grades 1-4 Adverse Reactions Occurring at Higher Incidence (≥ 5%) in Patients
Receiving Avastin with Chemotherapy vs. Chemotherapy Alone in Study GOG-0240
Adverse Reactiona Avastin with Chemotherapy Chemotherapy

(N=218) (N=222)
Hyperglycemia 26% 19%
Hypomagnesemia 24% 15%
Weight Decreased 21% 7%
Hyponatremia 19% 10%
Hypoalbuminemia 16% 11%
General disorders
Fatigue 80% 75%
Edema Peripheral 15% 22%
Infections and infestations
Urinary Tract Infection 22% 14%
Infection 10% 5%
Vascular disorders
Hypertension 29% 6%
Thrombosis 10% 3%
Headache 22% 13%
Dysarthria 8% 1%
Stomatitis 15% 10%
Proctalgia 6% 1%
Anal fistula 6% 0.0%
Neutropenia 12% 6%
Lymphopenia 12% 5%
Psychiatric disorders
Anxiety 17% 10%
Reproductive system and breast disorders
Pelvic pain 14% 8%
Epistaxis 17% 1%
Blood Creatinine Increased 16% 10%
Proteinuria 10% 3%
a NCI-CTC version 3
Grade 3−4 adverse reactions occurring at a higher incidence (≥ 2%) in 218 patients receiving Avastin
with chemotherapy compared to 222 patients receiving chemotherapy alone were abdominal pain
(12% vs. 10%), hypertension (11% vs. 0.5%), thrombosis (8% vs. 3%), diarrhea (6% vs. 3%), anal
fistula (4% vs. 0%), proctalgia (3% vs. 0%), urinary tract infection (8% vs. 6%), cellulitis (3% vs.
0.5%), fatigue (14% vs. 10%), hypokalemia (7% vs. 4%), hyponatremia (4% vs. 1%), dehydration
(4% vs. 0.5%), neutropenia (8% vs. 4%), lymphopenia (6% vs. 3%), back pain (6% vs. 3%), and
pelvic pain (6% vs. 1%).
Metastatic Colorectal Cancer (mCRC)
double-blind, active-controlled study (AVF2107g), which compared Avastin (5 mg/kg every
2 weeks) with bolus-IFL to placebo with bolus IFL in patients with mCRC. Patients were
randomized (1:1:1) to placebo with bolus IFL, Avastin with bolus IFL, or Avastin with 5
fluorouracil and leucovorin. The demographics of the safety population were similar to the
demographics of the efficacy population.
All Grade 3−4 adverse reactions and selected Grade 1−2 adverse reactions (i.e., hypertension,
proteinuria, thromboembolic events) were collected in the entire study population. Adverse reactions
are presented in Table 7.
Table 7: Grade 3−4 Adverse Reactions Occurring at Higher Incidence (≥ 2%) in Patients
Receiving Avastin vs. Placebo in Study AVF2107g
Avastin with IFL Placebo with IFL
Adverse Reactiona
(N=392) (N=396)
General disorders
Asthenia 10% 7%
Pain 8% 5%
Vascular disorders
Hypertension 12% 2%
Deep Vein Thrombosis 9% 5%
Intra-Abdominal 3% 1%
Thrombosis
Syncope 3% 1%
Diarrhea 34% 25%
Abdominal Pain 8% 5%
Constipation 4% 2%
Blood and lymphatic disorders
Leukopenia 37% 31%
Neutropenia 21% 14%
a NCI-CTC version 3
The safety of Avastin was evaluated in 521 patients in an open-label, active-controlled study
(E3200). Patients who were previously treated with irinotecan and fluorouracil for initial therapy for
metastatic colorectal cancer. Patients were randomized (1:1:1) to FOLFOX4, Avastin (10 mg/kg
every 2 weeks prior to FOLFOX4 on Day 1) with FOLFOX4, or Avastin alone (10 mg/kg every
2 weeks). Avastin was continued until disease progression or unacceptable toxicity.
The demographics of the safety population were similar to the demographics of the efficacy
population. The most frequent adverse reactions (selected Grade 3−5 non-hematologic and
Grade 4−5 hematologic) occurring at a higher incidence (≥ 2%) in patients receiving Avastin with
FOLFOX4 compared to FOLFOX4 alone were fatigue (19% vs. 13%), diarrhea (18% vs. 13%),
sensory neuropathy (17% vs. 9%), nausea (12% vs. 5%), vomiting (11% vs. 4%), dehydration (10%
vs. 5%), hypertension (9% vs. 2%), abdominal pain (8% vs. 5%), hemorrhage (5% vs. 1%), other
neurological (5% vs. 3%), ileus (4% vs. 1%) and headache (3% vs. 0%). These data are likely to
under-estimate the true adverse event rates due to the reporting mechanisms.
First-Line Non Squamous Non Small Cell Lung Cancer (NSCLC)

The safety of Avastin was evaluated as first-line treatment in 422 patients with unresectable NSCLC
who received at least one dose of Avastin in an active-controlled, open-label, multicenter trial
(E4599). Chemotherapy naïve patients with locally advanced, metastatic or recurrent non–squamous
NSCLC were randomized (1:1) to receive six 21 day cycles of paclitaxel and carboplatin with or
without Avastin (15 mg/kg every 3 weeks). After completion or upon discontinuation of
chemotherapy, patients randomized to receive Avastin continued to receive Avastin alone until
disease progression or until unacceptable toxicity. The trial excluded patients with predominant
squamous histology (mixed cell type tumors only), CNS metastasis, gross hemoptysis (1/2 teaspoon
or more of red blood), unstable angina, or receiving therapeutic anticoagulation. The demographics
of the safety population were similar to the demographics of the efficacy population.
Only Grade 3-5 non hematologic and Grade 4-5 hematologic adverse reactions were collected.
Grade 3-5 non hematologic and Grade 4-5 hematologic adverse reactions occurring at a higher
incidence (≥ 2%) in patients receiving Avastin with paclitaxel and carboplatin compared with
patients receiving chemotherapy alone were neutropenia (27% vs. 17%), fatigue (16% vs. 13%),
hypertension (8% vs. 0.7%), infection without neutropenia (7% vs. 3%), venous thromboembolism
(5% vs. 3%), febrile neutropenia (5% vs. 2%), pneumonitis/pulmonary infiltrates (5% vs. 3%),
infection with Grade 3 or 4 neutropenia (4% vs. 2%), hyponatremia (4% vs. 1%), headache (3% vs.
1%) and proteinuria (3% vs. 0%).
Recurrent Glioblastoma
EORTC 26101 was a multicenter, randomized, open-label study in patients with recurrent GBM
following radiotherapy and temozolomide of whom 278 patients received at least one dose of
Avastin and are considered safety evaluable. Patients were randomized (2:1) to receive Avastin
(10 mg/kg every 2 weeks) with lomustine or lomustine alone until disease progression or
unacceptable toxicity. The demographics of the safety population were similar to the demographics
of the efficacy population. In the Avastin with lomustine arm, 22% of patients discontinued
treatment due to adverse reactions compared with 10% of patients in the lomustine arm. In patients
receiving Avastin with lomustine, the adverse reaction profile was similar to that observed in other
approved indications.
6.2 Immunogenicity
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody
formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the
observed incidence of antibody (including neutralizing antibody) positivity in an assay may be
influenced by several factors, including assay methodology, sample handling, timing of sample
collection, concomitant medications, and underlying disease. For these reasons, comparison of the
incidence of antibodies to bevacizumab in the studies described below with the incidence of
antibodies in other studies or to other products may be misleading.
In clinical studies for adjuvant treatment of a solid tumor, 0.6% (14/2323) of patients tested positive
for treatment-emergent anti-bevacizumab antibodies as detected by an electrochemiluminescent
(ECL) based assay. Among these 14 patients, three tested positive for neutralizing antibodies against
bevacizumab using an enzyme-linked immunosorbent assay (ELISA). The clinical significance of
these anti-bevacizumab antibodies is not known.
6.3 Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Avastin. Because
these reactions are reported voluntarily from a population of uncertain size, it is not always possible
to reliably estimate their frequency or establish a causal relationship to drug exposure.
Body as a Whole: Polyserositis

Cardiovascular: Pulmonary hypertension, Mesenteric venous occlusion
Gastrointestinal: Gastrointestinal ulcer, Intestinal necrosis, Anastomotic ulceration
Hemic and lymphatic: Pancytopenia
Hepatobiliary disorders: Gallbladder perforation
Musculoskeletal and Connective Tissue Disorders: Osteonecrosis of the jaw
Renal: Renal thrombotic microangiopathy (manifested as severe proteinuria)
Respiratory: Nasal septum perforation
7 DRUG INTERACTIONS
No clinically meaningful effect on the pharmacokinetics of irinotecan or its active metabolite SN38,
interferon alfa, carboplatin or paclitaxel was observed when Avastin was administered in
combination with these drugs; however, 3 of the 8 patients receiving Avastin with paclitaxel and
carboplatin had lower paclitaxel exposure after four cycles of treatment (at Day 63) than those at
Day 0, while patients receiving paclitaxel and carboplatin alone had a greater paclitaxel exposure at
Day 63 than at Day 0.
8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
Risk Summary
Avastin may cause fetal harm based on findings from animal studies and its mechanism of action.
[see Clinical Pharmacology (12.1)]. Limited postmarketing reports describe cases of fetal
malformations with use of Avastin in pregnancy; however, these reports are insufficient to determine
drug associated risks. In animal reproduction studies, intravenous administration of bevacizumab to
pregnant rabbits every 3 days during organogenesis at doses approximately 1 to 10 times the clinical
dose of 10 mg/kg produced fetal resorptions, decreased maternal and fetal weight gain and multiple
congenital malformations including corneal opacities and abnormal ossification of the skull and
skeleton including limb and phalangeal defects [see Data]. Furthermore, animal models link
angiogenesis and VEGF and VEGFR-2 to critical aspects of female reproduction, embryofetal
development, and postnatal development. Advise pregnant women of the potential risk to a fetus.
The background risk of major birth defects and miscarriage for the indicated population is unknown.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage
in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data
Animal Data
Pregnant rabbits dosed with 10 mg/kg to 100 mg/kg bevacizumab (approximately 1 to 10 times the
clinical dose of 10 mg/kg) every three days during the period of organogenesis (gestation day 6−18)
exhibited decreases in maternal and fetal body weights and increased number of fetal resorptions.
There were dose-related increases in the number of litters containing fetuses with any type of
malformation (42% for the 0 mg/kg dose, 76% for the 30 mg/kg dose, and 95% for the 100 mg/kg
dose) or fetal alterations (9% for the 0 mg/kg dose, 15% for the 30 mg/kg dose, and 61% for the 100
mg/kg dose). Skeletal deformities were observed at all dose levels, with some abnormalities
including meningocele observed only at the 100 mg/kg dose level. Teratogenic effects included:
reduced or irregular ossification in the skull, jaw, spine, ribs, tibia and bones of the paws; fontanel,
rib and hindlimb deformities; corneal opacity; and absent hindlimb phalanges.
8.2 Lactation
Risk Summary
No data are available regarding the presence of bevacizumab in human milk, the effects on the breast
fed infant, or the effects on milk production. Human IgG is present in human milk, but published
data suggest that breast milk antibodies do not enter the neonatal and infant circulation in substantial
amounts. Because of the potential for serious adverse reactions in breastfed infants from
bevacizumab, advise women not to breastfeed during treatment with Avastin and for 6 months
following the final dose.
8.3 Females and Males of Reproductive Potential

Contraception
Females
Avastin may cause fetal harm when administered to a pregnant woman. [see Use in Specific
Populations (8.1).] Advise female of reproductive potential to use effective contraception during
treatment with Avastin and for 6 months after the last dose of Avastin.
Infertility
Females
Avastin increases the risk of ovarian failure and may impair fertility. Inform females of reproductive
potential of the risk of ovarian failure prior to the first-dose of Avastin. Long-term effects of Avastin
on fertility are not known.
In a clinical study of 179 premenopausal women randomized to receive chemotherapy with or

without Avastin, the incidence of ovarian failure was higher in patients who received Avastin with
chemotherapy (34%) compared patients who received chemotherapy alone (2%). After discontinuing
Avastin with chemotherapy, recovery of ovarian function occurred in 22% of these patients.
[see Warnings and Precautions (5.11), Adverse Reactions (6.1).]
8.4 Pediatric Use

The safety and effectiveness of Avastin in pediatric patients have not been established. In published
literature reports, cases of non-mandibular osteonecrosis have been observed in patients under the
age of 18 years who have received Avastin. Avastin is not approved for use in patients under the age
of 18 years.
Antitumor activity was not observed among eight pediatric patients with relapsed glioblastoma
receiving bevacizumab and irinotecan.
Animal Data
Juvenile cynomolgus monkeys with open growth plates exhibited physeal dysplasia following 4 to
26 weeks exposure at 0.4 to 20 times the recommended human dose (based on mg/kg and exposure).
The incidence and severity of physeal dysplasia were dose-related and were partially reversible upon
cessation of treatment.
8.5 Geriatric Use

In an exploratory, pooled analysis of 1745 patients from five randomized, controlled studies, 35%
patients were ≥ 65 years old. The overall incidence of arterial thromboembolic events was increased
in all patients receiving Avastin with chemotherapy as compared to those receiving chemotherapy
alone, regardless of age; however, the increase in the incidence of ATE was greater in
patients ≥ 65 years (8% vs. 3%) as compared to patients < 65 years (2% vs. 1%) [see Warnings and
Precautions (5.4)].
10 OVERDOSAGE
No information is available concerning Avastin overdosage.
11 DESCRIPTION
Bevacizumab is vascular endothelial growth factor directed antibody. Bevacizumab is a recombinant
humanized monoclonal IgG1 antibody that contains human framework regions and murine
complementarity-determining regions. Bevacizumab has an approximate molecular weight of
149 kDa. Bevacizumab is produced in a mammalian cell (Chinese Hamster Ovary) expression
system in a nutrient medium containing the antibiotic gentamicin. Gentamicin is not detectable in the
final product.
Avastin (bevacizumab) Injection for intravenous use is a sterile, clear to slightly opalescent,
colorless to pale brown solution. Avastin is supplied in 100 mg and 400 mg preservative-free,
single-dose vials to deliver 4 mL or 16 mL of Avastin (25 mg/mL).
The 100 mg product is formulated in 240 mg α,α-trehalose dihydrate, 23.2 mg sodium phosphate
(monobasic, monohydrate), 4.8 mg sodium phosphate (dibasic, anhydrous), 1.6 mg polysorbate 20,
and Water for Injection, USP.
The 400 mg product is formulated in 960 mg α,α-trehalose dihydrate, 92.8 mg sodium phosphate
(monobasic, monohydrate), 19.2 mg sodium phosphate (dibasic, anhydrous), 6.4 mg polysorbate 20,
and Water for Injection, USP.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on
the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell
proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of
bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of
microvascular growth and inhibition of metastatic disease progression.
12.3 Pharmacokinetics
The pharmacokinetic profile of bevacizumab was assessed using an assay that measures total serum
bevacizumab concentrations (i.e., the assay did not distinguish between free bevacizumab and
bevacizumab bound to VEGF ligand). Based on a population pharmacokinetic analysis of 491
patients who received 1 to 20 mg/kg of Avastin every week, every 2 weeks, or every 3 weeks,
bevacizumab pharmacokinetics are linear and the predicted time to reach more than 90% of steady
state concentration is 84 days. The accumulation ratio following a dose of 10 mg/kg once every
2 weeks is 2.8.
Population simulations of bevacizumab exposures provide a median trough concentration of 80.3

mcg/mL on Day 84 (10th, 90th percentile: 45, 128) following a dose of 5 mg/kg once every two
weeks.
Distribution
The mean (% coefficient of variation [CV%]) central volume of distribution is 2.9 (22%) L.
Elimination
The mean (CV%) clearance is 0.23 (33) L/day. The estimated half-life is 20 days (11 to 50 days).
Specific Populations
The clearance of bevacizumab varied by body weight, sex, and tumor burden. After correcting for
body weight, males had a higher bevacizumab clearance (0.26 L/day vs. 0.21 L/day) and a larger
central volume of distribution (3.2 L vs. 2.7 L) than females. Patients with higher tumor burden (at
or above median value of tumor surface area) had a higher bevacizumab clearance (0.25 L/day vs.
0.20 L/day) than patients with tumor burdens below the median. In AVF2107g, there was no
evidence of lesser efficacy (hazard ratio for overall survival) in males or patients with higher tumor
burden treated with Avastin as compared to females and patients with low tumor burden. Based on
data in specific populations, no dose adjustments for Avastin are needed.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
No studies have been conducted to assess potential of bevacizumab for carcinogenicity or
mutagenicity.
Bevacizumab may impair fertility. Female cynomolgus monkeys treated with 0.4 to 20 times the
recommended human dose of bevacizumab exhibited arrested follicular development or absent
corpora lutea, as well as dose-related decreases in ovarian and uterine weights, endometrial
proliferation, and the number of menstrual cycles. Following a 4- or 12-week recovery period, there
was a trend suggestive of reversibility. After the 12-week recovery period, follicular maturation
arrest was no longer observed, but ovarian weights were still moderately decreased. Reduced
endometrial proliferation was no longer observed at the 12-week recovery time point; however,
decreased uterine weight, absent corpora lutea, and reduced number of menstrual cycles remained
evident.
13.2 Animal Toxicology and/or Pharmacology

Rabbits dosed with bevacizumab exhibited reduced wound healing capacity. Using full-thickness
skin incision and partial thickness circular dermal wound models, bevacizumab dosing resulted in
reductions in wound tensile strength, decreased granulation and re-epithelialization, and delayed
time to wound closure.
14 CLINICAL STUDIES
Study AVF2107g
In a double-blind, active-controlled study [AVF2107g (NCT00109070)], 923 patients were
randomized (1:1:1) to placebo with bolus-IFL (irinotecan 125 mg/m2, 5-fluorouracil 500 mg/m2, and
leucovorin 20 mg/m2 given once weekly for 4 weeks every 6 weeks), Avastin (5 mg/kg every
2 weeks) with bolus-IFL, or Avastin (5 mg/kg every 2 weeks) with 5-fluorouracil and leucovorin.
Enrollment to the Avastin with 5-fluorouracil and leucovorin arm was discontinued after enrollment
of 110 patients in accordance with the protocol-specified adaptive design. Avastin was continued
until disease progression or unacceptable toxicity or for a maximum of 96 weeks. The main outcome
measure was overall survival (OS).
The median age was 60 years; 60% were male, 79% were White, 57% had an ECOG performance
status of 0, 21% had a rectal primary and 28% received prior adjuvant chemotherapy. The dominant
site of disease was extra-abdominal in 56% of patients and was the liver in 38% of patients.
The addition of Avastin improved survival across subgroups defined by age (< 65 years, ≥ 65 years)
and sex. Results are presented in Table 8 and Figure 1.
Table 8: Efficacy Results in Study AVF2107g
Efficacy Parameter Avastin with bolus-IFL Placebo with bolus-IFL

(N=402) (N=411)
Overall Survival
Median (months) 20.3 15.6
Hazard ratio 0.66
(95% CI) (0.54, 0.81)
p-valuea < 0.001
Progression Free Survival
Hazard ratio 0.54
(95% CI) (0.45, 0.66)
p-valuea < 0.0001
Overall Response Rate
Rate (%) 45% 35%
p-valueb < 0.01
Duration of Response
a
by stratified log rank test.
b 2
by χ test
Figure 1: Kaplan-Meier Curves for Duration of Survival in Metastatic Colorectal Cancer in

Study AVF2107g
Among the 110 patients randomized to Avastin with 5-fluorouracil and leucovorin, median OS was
18.3 months, median progression-free survival (PFS) was 8.8 months, overall response rate (ORR)
was 39%, and median duration of response was 8.5 months.
Study E3200
E3200 (NCT00025337) was a randomized, open-label, active-controlled study in 829 patients who
were previously treated with irinotecan and 5-fluorouracil for initial therapy for metastatic disease or
as adjuvant therapy. Patients were randomized (1:1:1) to FOLFOX4 (Day 1: oxaliplatin 85 mg/m2
and leucovorin 200 mg/m2 concurrently, then 5-fluorouracil 400 mg/m2 bolus followed by
600 mg/m2 continuously; Day 2: leucovorin 200 mg/m2, then 5-fluorouracil 400 mg/m2 bolus
followed by 600 mg/m2 continuously; every 2 weeks), Avastin (10 mg/kg every 2 weeks prior to
FOLFOX4 on Day 1) with FOLFOX4, or Avastin alone (10 mg/kg every 2 weeks). Avastin was
continued until disease progression or unacceptable toxicity. The main outcome measure was OS.
The Avastin alone arm was closed to accrual after enrollment of 244 of the planned 290 patients
following a planned interim analysis by the data monitoring committee based on evidence of
decreased survival compared to FOLFOX4 alone.
The median age was 61 years; 60% were male, 87% were White, 49% had an ECOG performance
status of 0, 26% received prior radiation therapy, and 80% received prior adjuvant chemotherapy,
99% received prior irinotecan with or without 5-fluorouracil for metastatic disease, and 1% received
prior irinotecan and 5-fluorouracil as adjuvant therapy.
The addition of Avastin to FOLFOX4 resulted in significantly longer survival as compared to

FOLFOX4 alone; median OS was 13.0 months vs. 10.8 months [hazard ratio (HR) 0.75 (95%
CI: 0.63, 0.89), p-value of 0.001 stratified log rank test] with clinical benefit seen in subgroups
defined by age (< 65 years, ≥ 65 years) and sex. PFS and ORR based on investigator assessment were
higher in patients receiving Avastin with FOLFOX4.
Study TRC-0301
The activity of Avastin with 5-fluorouracil (as bolus or infusion) and leucovorin was evaluated in a
single arm study [TRC-0301 (NCT00066846)] enrolling 339 patients with mCRC with disease
progression following both irinotecan- and oxaliplatin-based chemotherapy. Seventy-three percent of
patients received concurrent bolus 5-fluorouracil and leucovorin. One objective partial response was
verified in the first 100 evaluable patients for an ORR of 1% (95% CI: 0%, 5.5%).
Study ML18147
ML18147 (NCT00700102) was a prospective, randomized, open-label, multinational, controlled
study in 820 patients with histologically confirmed mCRC who had progressed on a first-line
Avastin containing regimen. Patients were excluded if they progressed within 3 months of initiating
first-line chemotherapy and if they received Avastin for less than 3 consecutive months in the first-
line setting. Patients were randomized (1:1) within 3 months after discontinuing Avastin as first-line
therapy to receive fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy
with or without Avastin (5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks). The choice of second-
line therapy was contingent upon first-line chemotherapy. Second-line therapy was administered
until progressive disease or unacceptable toxicity. The main outcome measure was OS. A secondary
outcome measure was ORR.
The median age was 63 years (21 to 84 years); 64% were male, 52% had an ECOG performance
status of 1, 44% had an ECOG performance status of 0, 58% received irinotecan-based therapy as
first-line treatment, 55% progressed on first-line treatment within 9 months, and 77% received their
last dose of Avastin as first-line treatment within 42 days of being randomized. Second-line
chemotherapy regimens were generally balanced between each arm.
The addition of Avastin to fluoropyrimidine-based chemotherapy resulted in a statistically

significant prolongation of OS and PFS. There was no significant difference in ORR. Results are
presented in Table 9 and Figure 2.
Table 9: Efficacy Results in Study ML18147
Avastin with Chemotherapy Chemotherapy

Efficacy Parameter
(N=409) (N=411)
Overall Survivala
Hazard ratio (95% CI) 0.81 (0.69, 0.94)
Progression-Free Survivalb
Hazard ratio (95% CI) 0.68 (0.59, 0.78)
a
p = 0.0057 by unstratified log rank test.
b
p-value < 0.0001 by unstratified log rank test.
Figure 2: Kaplan-Meier Curves for Duration of Survival in Metastatic Colorectal Cancer in

Study ML18147
14.2 Lack of Efficacy in Adjuvant Treatment of Colon Cancer

Lack of efficacy of Avastin as an adjunct to standard chemotherapy for the adjuvant treatment of
colon cancer was determined in two randomized, open-label, multicenter clinical studies.
The first study [BO17920 (NCT00112918)] was conducted in 3451 patients with high-risk stage II
and III colon cancer, who had undergone surgery for colon cancer with curative intent. Patients were
randomized to receive Avastin at a dose equivalent to 2.5 mg/kg/week on either a 2-weekly schedule
with FOLFOX4 (N=1155), or on a 3-weekly schedule with XELOX (N=1145) or FOLFOX4 alone
(N=1151). The main outcome measure was disease free survival (DFS) in patients with stage III
colon cancer.
The median age was 58 years; 54% were male, 84% were White and 29% were ≥ 65 years. Eighty-
three percent had stage III disease.
The addition of Avastin to chemotherapy did not improve DFS. As compared to FOLFOX4 alone,
the proportion of stage III patients with disease recurrence or with death due to disease progression
were numerically higher for patients receiving Avastin with FOLFOX4 or with XELOX. The hazard
ratios for DFS were 1.17 (95% CI: 0.98,1.39) for Avastin with FOLFOX4 versus FOLFOX4 alone
and 1.07 (95% CI: 0.90, 1.28) for Avastin with XELOX versus FOLFOX4 alone. The hazard ratios
for OS were 1.31 (95% CI: 1.03, 1.67) and 1.27 (95% CI: 1, 1.62) for the comparison of Avastin
with FOLFOX4 versus FOLFOX4 alone and Avastin with XELOX versus FOLFOX4 alone,
respectively. Similar lack of efficacy for DFS were observed in the Avastin-containing arms
compared to FOLFOX4 alone in the high-risk stage II cohort.
In a second study [NSABP-C-08 (NCT00096278)], patients with stage II and III colon cancer who
had undergone surgery with curative intent, were randomized to receive either Avastin administered
at a dose equivalent to 2.5 mg/kg/week with mFOLFOX6 (N=1354) or mFOLFOX6 alone
(N=1356). The median age was 57 years, 50% were male and 87% White. Seventy-five percent had
stage III disease. The main efficacy outcome was DFS among stage III patients. The HR for DFS
was 0.92 (95% CI: 0.77, 1.10). OS was not significantly improved with the addition of Avastin to
mFOLFOX6 [HR 0.96 (95% CI: 0.75,1.22)].
14.3 First-Line Non–Squamous Non–Small Cell Lung Cancer (NSCLC)

Study E4599
The safety and efficacy of Avastin as first-line treatment of patients with locally advanced,
metastatic, or recurrent non–squamous NSCLC was studied in a single, large, randomized,
active-controlled, open-label, multicenter study [E4599 (NCT00021060)]. A total of 878
chemotherapy-naïve patients with locally advanced, metastatic or recurrent non–squamous NSCLC
were randomized (1:1) to receive six 21-day cycles of paclitaxel (200 mg/m2) and carboplatin
(AUC 6) with or without Avastin 15 mg/kg. After completing or discontinuing chemotherapy,
patients randomized to receive Avastin continued to receive Avastin alone until disease progression
or until unacceptable toxicity. The trial excluded patients with predominant squamous histology
(mixed cell type tumors only), CNS metastasis, gross hemoptysis (1/2 teaspoon or more of red
blood), unstable angina, or receiving therapeutic anticoagulation. The main outcome measure was
duration of survival.
The median age was 63 years; 54% were male, 43% were ≥ 65 years, and 28% had ≥ 5% weight loss
at study entry. Eleven percent had recurrent disease. Of the 89% with newly diagnosed NSCLC,
12% had Stage IIIB with malignant pleural effusion and 76% had Stage IV disease.
OS was statistically significantly longer for patients receiving Avastin with paclitaxel and
carboplatin compared with those receiving chemotherapy alone. Median OS was 12.3 months vs.
10.3 months [HR 0.80 (95% CI: 0.68, 0.94), final p-value of 0.013, stratified log-rank test]. Based on
investigator assessment which was not independently verified, patients were reported to have longer
PFS with Avastin with paclitaxel and carboplatin compared to chemotherapy alone. Results are
presented in Figure 3.
Figure 3: Kaplan-Meier Curves for Duration of Survival in First-Line Non-Squamous Non-
Small Cell Lung Cancer in Study E4599
In an exploratory analysis across patient subgroups, the impact of Avastin on OS was less robust in
the following subgroups: women [HR 0.99 (95% CI: 0.79, 1.25)], patients ≥ 65 years [HR 0.91 (95%
CI: 0.72, 1.14)] and patients with ≥ 5% weight loss at study entry [HR 0.96 (95% CI: 0.73, 1.26)].
Study BO17704
The safety and efficacy of Avastin in patients with locally advanced, metastatic or recurrent
non-squamous NSCLC, who had not received prior chemotherapy was studied in another
randomized, double-blind, placebo controlled study [BO17704 (NCT00806923)]. A total of
1043 patients were randomized (1:1:1) to receive cisplatin and gemcitabine with placebo, Avastin
7.5 mg/kg or Avastin 15 mg/kg. The main outcome measure was PFS. Secondary outcome measure
was OS.
The median age was 58 years; 36% were female and 29% were ≥ 65 years. Eight percent had
recurrent disease and 77% had Stage IV disease.
PFS was significantly higher in both Avastin-containing arms compared to the placebo arm [HR
0.75 (95% CI 0.62, 0.91), p-value of 0.0026 for Avastin 7.5 mg/kg and HR 0.82 (95% CI 0.68; 0.98),
p-value of 0.0301 for Avastin 15 mg/kg]. The addition of Avastin to cisplatin and gemcitabine failed
to demonstrate an improvement in the duration of OS [HR 0.93 (95% CI: 0.78; 1.11), p-value of
0.420 for Avastin 7.5 mg/kg and HR 1.03 (95% CI: 0.86, 1.23), p-value of 0.761 for Avastin
15 mg/kg].

Study EORTC 26101
The safety and efficacy of Avastin were evaluated in a multicenter, randomized (2:1), open-label
study in patients with recurrent GBM (EORTC 26101, NCT01290939). Patients with first
progression following radiotherapy and temozolomide were randomized (2:1) to receive Avastin
(10 mg/kg every 2 weeks) with lomustine (90 mg/m2 every 6 weeks) or lomustine (110 mg/m2 every
6 weeks) alone until disease progression or unacceptable toxicity. Randomization was stratified by
World Health Organization performance status (0 vs. >0), steroid use (yes vs. no), largest tumor
diameter (≤ 40 vs. > 40 mm), and institution. The main outcome measure was OS. Secondary
outcome measures were investigator-assessed PFS and ORR per the modified Response Assessment
in Neuro-oncology (RANO) criteria, health related quality of life (HRQoL), cognitive function, and
corticosteroid use.
A total of 432 patients were randomized to receive lomustine alone (N=149) or Avastin with
lomustine (N=283). The median age was 57 years; 24.8% of patients were ≥ 65 years. The majority
of patients with were male (61%); 66% had a WHO performance status score > 0; and in 56% the
largest tumor diameter was ≤ 40 mm. Approximately 33% of patients randomized to receive
lomustine received Avastin following documented progression.
No difference in OS (HR 0.91, p -value of 0.4578) was observed between arms; therefore, all
secondary outcome measures are descriptive only. PFS was longer in the Avastin with lomustine
arm [HR 0.52 (95% CI: 0.41, 0.64)] with a median PFS of 4.2 months in the Avastin with lomustine
arm and 1.5 months in the lomustine arm. Among the 50% of patients receiving corticosteroids at the
time of randomization, a higher percentage of patients in the Avastin with lomustine arm
discontinued corticosteroids (23% vs. 12%).
Study AVF3708g and Study NCI 06-C-0064E

One single arm single center study (NCI 06-C-0064E) and a randomized noncomparative
multicenter study [AVF3708g (NCT00345163)] evaluated the efficacy and safety of Avastin 10
mg/kg every 2 weeks in patients with previously treated GBM. Response rates in both studies were
evaluated based on modified WHO criteria that considered corticosteroid use. In AVF3708g, the
response rate was 25.9% (95% CI: 17%, 36.1%) with a median duration of response of 4.2 months
(95% CI: 3, 5.7). In Study NCI 06-C-0064E, the response rate was 19.6% (95% CI: 10.9%, 31.3%)
with a median duration of response of 3.9 months (95% CI: 2.4, 17.4).

Study BO17705
Patients with treatment-naïve mRCC were evaluated in a multicenter, randomized, double-blind,
international study [BO17705 (NCT00738530)] comparing interferon alfa Avastin versus placebo. A
total of 649 patients who had undergone a nephrectomy were randomized (1:1) to receive either
Avastin (10 mg/kg every 2 weeks; N = 327) or placebo (every 2 weeks; N = 322) with interferon alfa
(9 MIU subcutaneously three times weekly for a maximum of 52 weeks). Patients were treated until
disease progression or unacceptable toxicity. The main outcome measure was investigator-assessed
PFS. Secondary outcome measures were ORR and OS.
The median age was 60 years (18 to 82 years); 70% were male and 96% were White. The study
population was characterized by Motzer scores as follows: 28% favorable (0), 56% intermediate
(1-2), 8% poor (3−5), and 7% missing.
PFS was statistically significantly prolonged among patients receiving Avastin compared to placebo;
median PFS was 10.2 months vs. 5.4 months [HR 0.60 (95% CI: 0.49, 0.72), p-value < 0.0001,
stratified log-rank test]. Among the 595 patients with measurable disease, ORR was also
significantly higher (30% vs. 12%, p-value < 0.0001, stratified CMH test). There was no
improvement in OS based on the final analysis conducted after 444 deaths, with a median OS of
23 months in the patients receiving Avastin with interferon alfa and 21 months in patients receiving
interferon alone [HR 0.86, (95% CI 0.72, 1.04)]. Results are presented in Figure 4.
Figure 4: Kaplan-Meier Curves for Progression-Free Survival in Metastatic Renal Cell
Carcinoma in Study BO17705

Study GOG-0240
Patients with persistent, recurrent, or metastatic cervical cancer were evaluated in a randomized,
four-arm, multi-center study comparing Avastin with chemotherapy versus chemotherapy alone
[GOG-0240 (NCT00803062)]. A total of 452 patients were randomized (1:1:1:1) to receive
paclitaxel and cisplatin with or without Avastin, or paclitaxel and topotecan with or without Avastin.
The dosing regimens for Avastin, paclitaxel, cisplatin and topotecan were as follows:
• Day 1: Paclitaxel 135 mg/m2 over 24 hours, Day 2: cisplatin 50 mg/m2 with Avastin;
• Day 1: Paclitaxel 175 mg/m2 over 3 hours, Day 2: cisplatin 50 mg/m2 with Avastin;
• Day 1: Paclitaxel 175 mg/m2 over 3 hours with cisplatin 50 mg/m2 with Avastin;
• Day 1: Paclitaxel 175 mg/m2 over 3 hours with Avastin, Days 1-3: topotecan IV 0.75 mg/m2
over 30 minutes
Patients were treated until disease progression or unacceptable adverse reactions. The main outcome
measure was OS. Secondary outcome measures included ORR.
The median age was 48 years (20 to 85 years). Of the 452 patients randomized at baseline, 78% of
patients were White, 80% had received prior radiation, 74% had received prior chemotherapy
concurrent with radiation, and 32% had a platinum-free interval of less than 6 months. Patients had a
GOG performance status of 0 (58%) or 1 (42%). Demographic and disease characteristics were
balanced across arms.
Results are presented in Table 10 and Figure 5.

Figure 5: Kaplan-Meier Curves for Overall Survival in Persistent, Recurrent, or Metastatic
Cervical Cancer in Study GOG-0240
Table 10: Efficacy Results in Study GOG-0240
Efficacy Parameter Avastin with Chemotherapy

Chemotherapy (N=225)
(N=227)
Overall Survival
Median (months)a 16.8 12.9
Hazard ratio [95% CI] 0.74 [0.58;0.94]
(p-valueb = 0.0132)
a
Kaplan-Meier estimates.
b
log-rank test (stratified).
The ORR was higher in patients who received Avastin with chemotherapy [45% (95% CI: 39, 52)]
compared to patients who received chemotherapy alone [34% (95% CI: 28,40)].
Efficacy Parameter Topotecan and Cisplatin and Paclitaxel

Paclitaxel with or with or without Avastin
without Avastin
(N=229)
(N=223)
Overall Survival
Median (months)a 13.3 15.5
Hazard ratio [95% CI] 1.15 [0.91, 1.46]
p-value=0.23
a
Kaplan-Meier estimates.
The HR for OS with Avastin with cisplatin and paclitaxel as compared to cisplatin and paclitaxel
alone was 0.72 (95% CI: 0.51,1.02). The HR for OS with Avastin with topotecan and paclitaxel as
compared to topotecan and paclitaxel alone was 0.76 (95% CI: 0.55, 1.06).
14.7 Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal

Cancer
Study MO22224
Avastin was evaluated in a multicenter, open-label, randomized study [MO22224 (NCT00976911)]
comparing Avastin with chemotherapy versus chemotherapy alone in patients with
platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that
recurred within <6 months from the most recent platinum-based therapy (N=361). Patients had
received no more than 2 prior chemotherapy regimens. Patients received one of the following
chemotherapy regimens at the discretion of the investigator: paclitaxel (80 mg/m2 on days 1, 8, 15
and 22 every 4 weeks; pegylated liposomal doxorubicin 40 mg/m2 on day 1 every 4 weeks; or
topotecan 4 mg/m2 on days 1, 8 and 15 every 4 weeks or 1.25 mg/m2 on days 1-5 every 3 weeks).
Patients were treated until disease progression, unacceptable toxicity, or withdrawal. Forty percent
of patients on the chemotherapy alone arm received Avastin alone upon progression. The main
outcome measure was investigator-assessed PFS. Secondary outcome measures were ORR and OS.
The median age was 61 years (25 to 84 years) and 37% of patients were ≥65 years.
Seventy-nine percent had measurable disease at baseline, 87% had baseline CA-125 levels ≥2 times
ULN and 31% had ascites at baseline. Seventy-three percent had a platinum-free interval (PFI) of 3
months to 6 months and 27% had PFI of <3 months. ECOG performance status was 0 for 59%, 1 for
34% and 2 for 7% of the patients.
The addition of Avastin to chemotherapy demonstrated a statistically significant improvement in

investigator-assessed PFS, which was supported by a retrospective independent review analysis.
Results for the ITT population are presented in Table 12 and Figure 6. Results for the separate
chemotherapy cohorts are presented in Table 13.
Table 12: Efficacy Results in Study MO22224
Avastin with
Efficacy Parameter Chemotherapy Chemotherapy
(N=179) (N=182)
PFS per Investigator
Median (95% CI), in months 6.8 (5.6, 7.8) 3.4 (2.1, 3.8)
HR (95% CI)a 0.38 (0.30, 0.49)
p-value b <0.0001
Overall Survival
Median (95% CI), in months 16.6 (13.7, 19.0) 13.3 (11.9, 16.4)
HR (95% CI)a 0.89 (0.69, 1.14)
Number of Patients with 142 144
Measurable Disease at Baseline
Rate, % (95% CI) 28% (21%, 36%) 13% (7%, 18%)
Median, in months 9.4 5.4
a
per stratified Cox proportional hazards model
b
per stratified log rank test
Figure 6: Kaplan-Meier Curves for Investigator-Assessed Progression-Free Survival in

Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal
Cancer in Study MO22224
Table 13: Efficacy Results in Study MO22224 by Chemotherapy
Efficacy Paclitaxel Topotecan Pegylated Liposomal
Parameter Doxorubicin
Avastin with Chemotherapy Avastin with Chemotherapy Avastin with Chemotherapy
Chemotherapy Chemotherapy Chemotherapy
(N=60) (N=55) (N=57) (N=63) (N=62) (N=64)
Progression-Free Survival (per Investigator)
Median
9.6 3.9 6.2 2.1 5.1 3.5
(months)
(7.8, 11.5) (3.5, 5.5) (5.3, 7.6) (1.9, 2.3) (3.9, 6.3) (1.9, 3.9)
(95% CI)
Hazard 0.47 0.24 0.47
a (0.31, 0.72) (0.15, 0.38) (0.32, 0.71)
ratio
(95% CI)
Overall Survival
Median
22.4 13.2 13.8 13.3 13.7 14.1
(months)
(16.7, 26.7) (8.2, 19.7) (11.0, 18.3) (10.4, 18.3) (11.0, 18.3) (9.9, 17.8)
(95% CI)
Hazard 0.64 1.12 0.94
a (0.41, 1.01) (0.73, 1.73) (0.63, 1.42)
ratio
(95% CI)
Number of
patients
with
45 43 46 50 51 51
measurable
disease at
baseline
Rate, %
53 (39, 68) 30 (17, 44) 17 (6, 28) 2 (0, 6) 16 (6, 26) 8 (0, 15)
(95% CI)
Median
11.6 6.8 5.2 NE 8.0 4.6
(months)
a
per stratified Cox proportional hazards model
NE= Not Estimable
14.8 Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal

Cancer
Study AVF4095g
AVF4095g (NCT00434642) was a randomized, double-blind, placebo-controlled study studying
Avastin with chemotherapy versus chemotherapy alone in the treatment of patients with platinum-
sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not
received prior chemotherapy in the recurrent setting or prior bevacizumab treatment (N=484).
Patients were randomized (1:1) to receive Avastin (15 mg/kg day 1) or placebo every 3 weeks with
carboplatin (AUC 4, day 1) and gemcitabine (1000 mg/m2 on days 1 and 8) a for 6 to 10 cycles
followed by Avastin or placebo alone until disease progression or unacceptable toxicity.
The main outcome measures were investigator-assessed PFS. Secondary outcome measures were
ORR and OS.
The median age was 61 years (28 to 87 years) and 37% of patients were ≥65 years. All patients had
measurable disease at baseline, 74% had baseline CA-125 levels >ULN (35 U/mL). The platinum-
free interval (PFI) was 6 months to 12 months in 42 % of patients and >12 months in 58% of
patients. The ECOG performance status was 0 or 1 for 99.8% of patients.
A statistically significant prolongation in PFS was demonstrated among patients receiving Avastin
with chemotherapy compared to those receiving placebo with chemotherapy (Table 14 and Figure
7). Independent radiology review of PFS was consistent with investigator assessment [HR 0.45 (95%
CI: 0.35, 0.58)]. OS was not significantly improved with the addition of Avastin to chemotherapy
[HR 0.95 (95% CI: 0.77, 1.17)].
Table 14: Efficacy Results in Study AVF4095g

Efficacy Parameter Avastin with Gemcitabine Placebo with Gemcitabine
and Carboplatin and Carboplatin
(N=242) (N=242)
Progression Free Survival
Median PFS (months) 12.4 8.4
Hazard ratio 0.46
(95% CI) (0.37, 0.58)
p-value < 0.0001
% patients with overall
78% 57%
response
p-value < 0.0001
Figure 7: Kaplan-Meier Curves for Progression Free Survival in Platinum-Sensitive Recurrent

Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Study AVF4095g
Study GOG-0213
Study GOG-0213 (NCT00565851) was a randomized, controlled, open-label study of Avastin with
chemotherapy versus chemotherapy alone in the treatment of patients with platinum-sensitive
recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have not received
more than one previous regimen of chemotherapy (N=673). Patients were randomized (1:1) to
receive carboplatin (AUC 5) and paclitaxel (175 mg/m2 IV over 3 hours) every 3 weeks for 6 to 8
cycles (N=336) or Avastin (15 mg/kg) every 3 weeks with carboplatin (AUC 5) and paclitaxel (175
mg/m2 IV over 3 hours) for 6 to 8 cycles followed by Avastin (15 mg/kg every 3 weeks) as a single
agent until disease progression or unacceptable toxicity. The main outcome measure was OS. Other
outcome measures were investigator-assessed PFS, and ORR.
The median age was 60 years (23 to 85 years) and 33% of patients were ≥ 65 years. Eighty-
three percent had measurable disease at baseline and 74% had abnormal CA-125 levels at baseline.
Ten percent of patients had received prior bevacizumab. Twenty-six percent had a PFI of 6 months
to 12 months and 74% had a PFI of >12 months. GOG performance status was 0 or 1 for 99% of
patients.
Results are presented in Table 15 and Figure 8.
Avastin with
Efficacy Parameter
Carboplatin and Paclitaxel Carboplatin and Paclitaxel
(N=337) (N=336)
Overall Survival
Median OS (months) 42.6 37.3
Hazard ratio (95% CI) (IVRS)a 0.84 (0.69, 1.01)
Hazard ratio (95% CI) (eCRF)b 0.82 (0.68, 0.996)
Progression-free Survival
Median PFS (months) 13.8 10.4
a
Hazard ratio (95% CI) (IVRS) 0.61 (0.51, 0.72)
Number of patients with 274 286
measurable disease at baseline
Rate, % 213 (78%) 159 (56%)
a
HR was estimated from Cox proportional hazards models stratified by the duration of treatment free-interval prior to enrolling onto
this study per IVRS (interactive voice response system) and secondary surgical debulking status.
b
HR was estimated from Cox proportional hazards models stratified by the duration of platinum free-interval prior to enrolling onto
this study per eCRF (electronic case report form) and secondary surgical debulking status.
Figure 8: Kaplan Meier Curves for Overall Survival in Platinum-Sensitive Recurrent
Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Study GOG-0213
16 HOW SUPPLIED/STORAGE AND HANDLING

Avastin (bevacizumab) Injection is a clear to slightly opalescent, colorless to pale brown, sterile
solution for intravenous infusion supplied as single-dose vials in the following strengths:
100 mg/4 mL (NDC 50242-060-01) and 400 mg/16 mL (NDC 50242-061-01). Each carton contains
one vial.
Store refrigerated at 2−8°C (36−46°F) in the original carton until time of use to protect from light.
Do not freeze or shake the vial.
17 PATIENT COUNSELING INFORMATION
Gastrointestinal Perforations and Fistulae: Avastin may increase the risk of developing
gastrointestinal perforations and fistulae. Advise patients to immediately contact their health care
provider for high fever, rigors, persistent or severe abdominal pain, severe constipation, or vomiting
Surgery and Wound Healing Complications: Avastin can increase the risk of wound healing
complications. Advise patients that Avastin should not be used for at least 28 days before or after
surgery and until surgical wounds are fully healed [see Warnings and Precautions (5.2)].
Hemorrhage: Avastin can increase the risk of hemorrhage. Advise patients to immediately contact
their health care provider for signs and symptoms of serious or unusual bleeding including coughing
or spitting blood [see Warnings and Precautions (5.3)].
Arterial and Venous Thromboembolism: Avastin increases the risk of arterial and venous
thromboembolic events. Advise patients to immediately contact their health care provider for signs
and symptoms of arterial or venous thromboembolism [see Warnings and Precautions (5.4, 5.5)].
Hypertension: Avastin can increase blood pressure. Advise patients that they will undergo routine
blood pressure monitoring and to contact their healthcare provider if they experience changes in
blood pressure [see Warnings and Precautions (5.6)].
Posterior Reversible Leukoencephalopathy Syndrome: Posterior reversible encephalopathy
syndrome (PRES) has been associated with Avastin treatment. Advise patients to immediately
contact their health care provider for new onset or worsening neurological function [see Warnings
and Precautions (5.7)].
Renal Injury and Proteinuria: Avastin increases the risk of proteinuria and renal injury, including
nephrotic syndrome. Advise patients that treatment with Avastin requires regular monitoring of renal
function and to contact their health care provider for proteinuria or signs and symptoms of nephrotic
syndrome [see Warnings and Precautions (5.8)].
Infusion Reactions: Avastin can cause infusion reactions. Advise patients to contact their healthcare
provider immediately for signs or symptoms of infusion reactions [see Warnings and Precautions
(5.9)].
Congestive Heart Failure: Avastin can increase the risk of developing congestive heart failure.
Advise patients to contact their healthcare provider immediately for signs and symptoms of CHF
Embryo-Fetal Toxicity: Advise female patients that Avastin may cause fetal harm and to inform
their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions
(5.10), Use in Specific Populations (8.1)]. Advise females of reproductive potential to use effective
contraception during treatment with Avastin and for 6 months after the last dose of Avastin [see Use
in Specific Populations (8.3)].
Ovarian Failure: Avastin may lead to ovarian failure. Advise patients of potential options for
preservation of ova prior to starting treatment [see Warnings and Precautions (5.11)].
Lactation: Advise lactating women not to breastfeed while taking Avastin or within 6 months
following their last dose of treatment [see Use in Specific Populations (8.2)].
Avastin (bevacizumab)
®
Manufactured by:
Genentech, Inc.
A Member of the Roche Group
1 DNA Way Avastin is a registered trademark of Genentech, Inc.
®
©
South San Francisco, CA 94080-4990 2016 Genentech, Inc.

Avastin Prescribing

Uploaded by

Copyright:

Available Formats

Avastin Prescribing

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Avastin Prescribing

Uploaded by

Copyright:

Available Formats

HIGHLIGHTS OF PRESCRIBING INFORMATION First-Line Non−squamous non−small cell lung cancer (2.

WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND

Hemorrhages: Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding,

1 INDICATIONS AND USAGE

Avastin, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based

1.2 First-Line Non-Squamous Non–Small Cell Lung Cancer (NSCLC)

1.3 Recurrent Glioblastoma (GBM)

1.4 Metastatic Renal Cell Carcinoma (mRCC)

1.5 Persistent, Recurrent, or Metastatic Cervical Cancer

2 DOSAGE AND ADMINISTRATION

2.2 Metastatic Colorectal Cancer (mCRC)

2.3 First-Line Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

2.4 Recurrent Glioblastoma (GBM)

2.5 Metastatic Renal Cell Carcinoma (mRCC)

2.6 Persistent, Recurrent, or Metastatic Cervical Cancer

2.7 Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

2.8 Dose Modifications for Adverse Reactions

Table 1: Dose Modifications for Adverse Reactions

Adverse Reaction Severity Dose Modification

Hypertension [see Warnings • Hypertensive crisis Discontinue Avastin

• Mild, clinically insignificant Decrease infusion rate

2.9 Preparation and Administration

3 DOSAGE FORMS AND STRENGTHS

5 WARNINGS AND PRECAUTIONS

5.2 Surgery and Wound Healing Complications

5.4 Arterial Thromboembolic Events

5.5 Venous Thromboembolic Events

5.7 Posterior Reversible Encephalopathy Syndrome (PRES)

5.8 Renal Injury and Proteinuria

5.9 Infusion Reactions

5.10 Embryo-Fetal Toxicity

5.11 Ovarian Failure

5.12 Congestive Heart Failure (CHF)

6.1 Clinical Trial Experience

Platinum-Resistant Recurrent Epithelia Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Avastin with Chemotherapy Chemotherapy

Avastin with Carboplatin and Placebo with Carboplatin and

Metastatic Renal Cell Carcinoma (mRCC)

Avastin with Interferon Placebo with Interferon

Persistent, Recurrent, or Metastatic Cervical Cancer

Adverse Reactiona Avastin with Chemotherapy Chemotherapy

First-Line Non Squamous Non Small Cell Lung Cancer (NSCLC)

Body as a Whole: Polyserositis

8 USE IN SPECIFIC POPULATIONS

8.3 Females and Males of Reproductive Potential

In a clinical study of 179 premenopausal women randomized to receive chemotherapy with or

8.4 Pediatric Use

8.5 Geriatric Use

Population simulations of bevacizumab exposures provide a median trough concentration of 80.3

13.2 Animal Toxicology and/or Pharmacology

Table 8: Efficacy Results in Study AVF2107g

Efficacy Parameter Avastin with bolus-IFL Placebo with bolus-IFL

Figure 1: Kaplan-Meier Curves for Duration of Survival in Metastatic Colorectal Cancer in

The addition of Avastin to FOLFOX4 resulted in significantly longer survival as compared to

The addition of Avastin to fluoropyrimidine-based chemotherapy resulted in a statistically

Avastin with Chemotherapy Chemotherapy

Figure 2: Kaplan-Meier Curves for Duration of Survival in Metastatic Colorectal Cancer in

14.2 Lack of Efficacy in Adjuvant Treatment of Colon Cancer

14.3 First-Line Non–Squamous Non–Small Cell Lung Cancer (NSCLC)

14.4 Recurrent Glioblastoma (GBM)